

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094378 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 209/88**

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/IN2004/000104

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
328/MAS/2003 21 April 2003 (21.04.2003) IN

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for the following desig-  
nation US
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): **MATRIX  
LABORATORIES LTD** [IN/IN]; 1-1-151/1, IV Floor,  
Sairam Towers, Alexander Road, Secunderabad 500 003,  
Andhra Pradesh (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMAN-  
JANEYULU**, Gorantla, Seeta [IN/IN]; Plot No-12,  
Sai Ansh Arcade, Durgavihar Colony, Tirumalgherry, Se-  
cunderabad 500 015 (IN). **KUMAR**, Indukuri, Venkata,  
Sunil [IN/IN]; Flat No-104, Raghavendra Towers, KPHB  
- VI Phase, Kukatpally, Hyderabad 500 072 (IN). **RAO**,  
Ketavarapu, Narasimha [IN/IN]; C3-521, Huda Colony,  
Chandanagar, Hyderabad 500 050 (IN). **KISHORE**, Jam-  
mula, Vera, Venkata, Krishna [IN/IN]; Flat No-102B,  
Vivekananda Apartments, Vivekananda Nagar Colony,  
hyderabad 500 072 (IN).

(74) Common Representative: **MATRIX LABORATORIES  
LTD**; RAO, CH., V. Ramana, Plot No. 38, Phase IV, Ida,  
Jeedimetla 500 055, Hyderabad (IN).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

(54) Title: PROCESS FOR THE PREPARATION OF CARVEDILOL FORM-II


(57) Abstract: The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprising a step of reacting 4-(2,3-epoxy propoxy) carbazole (II) with 2-(2-methoxy phenoxy) ethyl amine (III) followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.

WO 2004/094378 A1

### Process for the preparation of Carvedilol Form-II

The present invention relates to a new process involving minimal workup steps without using strong mineral acids and avoiding any degradation of the final product for the preparation of Carvedilol Form-II using novel Carvedilol salts.


Carvedilol is a non-selective  $\beta$ -adrenergic blocking agent with vasodilating activity. Carvedilol, ( $\pm$ ) 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxy phenoxy) ethyl] amino]-2-propanol [CAS Registry No 72956-09-3] has the structure of Formula -1




Formula -1

Carvedilol has a chiral center and can exist either as individual stereo isomer or in racemic form. Racemic Carvedilol is the active ingredient of COREG<sup>®</sup>, which is indicated for the treatment of congestive heart failure and hypertension. Both the racemate and stereoisomers may be obtained accordingly to procedures well known in the art (EP 0 127 099).

Various routes of synthesis have been used or suggested for the preparation of Carvedilol. Thus EP Q 004 920 reported the preparation of Carvedilol by reaction of 4-(2,3-epoxy propoxy) carbazole (II) with 2-(2-methoxy phenoxy) ethyl amine (III).




The above process produces a low yield of Carvedilol at least in part because in addition to Carvedilol, the process leads to the production of a bis impurity (IV) of the following structure




IV

5 EP 0 918 055 discloses that the Formation of the bis compound (IV) can be avoided by protecting the 'N' atom in 2-(2-methoxy phenoxy) ethylamine before reaction with 4-(2,3-epoxy propoxy) carbazole using a benzyl group as a protection group. The product benzyl-Carvedilol (V) Formed has to be debenzylated before the desired product Carvedilol is formed, where debenzylation is done by hydrogenative debenzylation. This procedure clearly  
10 introduces two additional steps in the synthesis, namely a benzylation and a debenzylation step.



**V**

15 PCT Publication WO 01 / 87837 describes the synthesis of Carvedilol by the reaction of 4-hydroxy carbazole with 5-chloromethyl-3- (2-(2-methoxy phenoxy) ethyl)-oxazolidin-2-one (VI). The 5-(9H-carbazol-4-yloxy methyl)-3-[2-(2-methoxy phenoxy) ethyl] oxazolidin-2-one (VII) Formed has to be hydrolyzed before the desired product Carvedilol is formed.



Moreover the preparation of 5-chloromethyl-3- [2-(2-methoxy phenoxy) ethyl]-oxazolidin-2-one (VI) requires sequence of reactions viz-reaction of 1,3-dichloro propan -2-ol with phenyl chloroformate followed by condensation of the resulting intermediate 2-methoxy phenoxy ethylamine thereby introducing a number additional steps in the synthesis. The publication also discloses hydrolysis of VII to Carvedilol in acidic medium and formation of salts.

PCT Publication WO 02/00216 describes the preparation of Carvedilol by reaction of 4-(2,3-epoxy propoxy) carbazole (II) with 2-(2-methoxy phenoxy) ethyl amine (III) in which the formation of bis compound (IV) can be avoided by taking large molar excess of III, the reaction being carried out in absence of solvent or in presence of solvents toluene, xylene and heptane. In the same publication the process for isolation of Carvedilol as crystalline hydrochloride is described to obtain the crystalline hydrochloride, hydrochloride hydrate and methyl ethyl ketone-solvate. The crude Carvedilol was isolated as hydrochloride salt after an elaborate work-up using strong acid like hydrochloric acid at pH 3.0 -5.0. The use of large molar excess of 2-(2-methoxy phenoxy) ethyl amine (III) (2.8 mol - 6.0 mol for 1.0 mol of 4-(2,3-epoxy propoxy) carbazole (II) makes this process uneconomical. Moreover the use of strong mineral acids for the salt formation can lead to decomposition of the product.

It has been a long standing need in industry to provide a process for the preparation of Carvedilol involving minimal workup steps without using strong mineral acids and avoiding any degradation of the final product.

The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts such as oxalate,

salicylate, comprising a step of reacting 4-(2,3-epoxy propoxy) carbazole (II) with 2-(2-methoxy phenoxy) ethyl amine (III) in molar ratio of about 1: 2 to about 1: 2.5, followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.

Fig. 1: X-ray diffraction pattern of the Carvedilol Form-II (Prepared as per the examples)

Fig. 2: FTIR spectrum of the Carvedilol Form -II (Prepared as per the examples)

Fig. 3: X-ray diffraction pattern of the Carvedilol Form-II

Fig. 4: FTIR spectrum of the Carvedilol Form-II

The essential features of the present invention is the process for the manufacture of Carvedilol Form-II using novel salts of Carvedilol which comprises of the steps:

1. Reaction of 4-(2,3-epoxy propoxy) carbazole with 2-(2-methoxy phenoxy) ethyl amine in the molar ratio of 1: 2.0 - 1: 2.5 in presence of solvent(s)
2. Adjustment of pH after the completion of reaction with organic acid(s) in presence of water, organic solvent(s) and isolation of the Carvedilol salts
3. Treatment of the salts with base(s) in a biphasic system of water and an water immiscible organic solvent(s)
4. Separation of the water immiscible organic solvent(s), isolation and crystallization of the Carvedilol from ethyl acetate

Both the crude Carvedilol and recrystallized Carvedilol obtained by the process of the present invention are in the polymorphic Form-II and are anhydrous, as is evident from the IR spectrum and X-Ray diffraction pattern.

The required 4-(2,3-epoxy propoxy) carbazole is prepared by the reaction of 4-hydroxy carbazole with epichlorohydrin in presence of potassium iodide and potassium carbonate in acetone at reflux temperature followed by removal of inorganics, distillation of the solvent and crystallization of the residue with methanol.

The reaction of 4-(2,3-epoxy propoxy) carbazole with 2-(2-methoxy phenoxy) ethylamine is carried out in presence of solvent at reflux temperature. The preferred molar ratio of 4-(2,3-epoxy propoxy) carbazole and 2-(2-methoxy phenoxy) ethylamine is 1: 20 to about 1: 2.5.

The solvents preferred are chlorobenzene, monoglyme (ethylene glycol diethyl ether), the reaction temperature is in the range of about 125°C to about 140°C, preferably about 130°C to about 133°C with chlorobenzene as solvent and in the range of about 80°C to about 90°C, preferably 87°C to about 90°C with monoglyme as solvent.

The work-up of reaction mass for isolation of salts varies based on the solvent medium. When the reaction medium is monoglyme, after the completion of reaction, the solvent is distilled off followed by addition of water and organic solvent(s), adjusting the pH of the reaction mass to about 2.0 to about 3.0 with organic acid(s) at temperature of about 40°C and cooling the reaction mass to about 20°C to about 25°C. The organic solvent is selected from isopropyl acetate or monochlorobenzene. When the reaction medium is chlorobenzene after completion of reaction, water is added and the pH is adjusted with organic acid(s) at above 40°C temperatures. The preferred organic acid is oxalic acid, salicylic acid or mixtures thereof and preferred temperature is about 45°C to about 50°C and the pH is about 2.5 to about 2.8. The precipitated Carvedilol salts (Carvedilol oxalate, Carvedilol salicylate) is isolated by filtration, centrifugation etc.

The Carvedilol salt is suspended in water, followed by addition of methylene chloride and basified to pH of about 9.0 to about 9.5 with suitable base(s) such as alkali, alkaline metal hydroxides, ammonia, organic bases such as triethyl amine, methyl amine at 20°C to about 25°C and stirred for about 1hr to about 2 hrs. The preferred base is the ammonia solution. The reaction mass is allowed to settle and the layers are separated. The organic layer is dried over dehydrating agents such as anhydrous sodium sulphate, magnesium sulphate. The solvent is distilled off from the dried organic layer. The residue obtained is crystallized from ethyl acetate by dissolving in hot condition and then cooling to 0°C – 10°C. The Carvedilol so

obtained may be further recrystallized from ethyl acetate to obtain a pharmaceutically acceptable quality.

The invention is now illustrated with non-limiting examples

5 **Example-1:**

**Step-1: Preparation of (2,3-Epoxy propoxy) carbazole**

100g (0.55 moles) of 4-hydroxy carbazole is dissolved in 600 ml of acetone. To that 188g (1.36 moles) potassium carbonate, 2.0g potassium iodide and 0.5g sodium dithionate are added under nitrogen. The reaction mass is refluxed for 1.0 hr, cooled to room temperature  
10 followed by the addition of 150g (1.62 moles) of epichlorohydrin through a dropping funnel over 40-45 min at room temp. The reaction mass is further refluxed for 32 hrs and then cooled to room temp and filtered. The above filtrate is evaporated followed by recrystallisation of the crude product from methanol.

Yield: 92 g (69.9% yield).

15 M.P: 121°C -126°C.

Purity: Above 98%

**Step-2: Preparation of 1-(9H-carbazol-4-yloxy)-3[[2-(2-methoxy phenoxy) ethyl] amino]-2- propanol oxalate (Carvedilol oxalate)**

20 174g (1.04 moles, 2.5 mol equivalents) of 2-(2-methoxy phenoxy) ethylamine is dissolved in 500ml of monochlorobenzene. The temperature is raised to 125°C under stirring. 100g (0.42 moles) of 4-(2,3-epoxy propoxy) carbazole is slowly added in five lots during 1 hr at reflux temperature. Refluxing is then carried on for two hrs. The reaction is monitored to completion by thin layer chromatography and then cooled to 90°C. 500ml water is then  
25 charged followed by cooling to 70°C. The pH of reaction mass is adjusted to 2.5-2.7 with 10% oxalic acid solution at 60°C -70°C. Stirring is done for one hr at 60°C -70°C. The reaction mass is cooled to room temp and maintained for two hrs. The material is filtered and washed with water and dried at 50°C -60°C.

Yield: 160 g (77% yield)

30 M.P: 186°C -188°C.

(C,63.01; H,5.72; N,5.68; Calculated for  $C_{26}H_{28}N_2O_8$  C,62.90; H,5.68; N,5.64; IR Analysis:  $cm^{-1}$  3447, 3056, 1607, 1456, 1264, 1216, 1187, and 1024 : $^1H$  NMR (300MHz, DMSO- $d_6$ )  $\delta$  11.25(1H,s, COOH), 8.2(1H,d, Ar-H), 7.44(1H,d, Ar-H), 7.30(2H,m, Ar-H), 7.10-7.15(2H,d, Ar-H), 6.80-7.05(4H,m, Ar-H), 6.66(1H,d, Ar-H), 4.25(2H,d, OCH $_2$ ), 4.15(2H,t, OCH $_2$ ), 3.70(3H,s, OCH $_3$ ), 3.13 (2H,t, CH $_2$ ), 3.11 (1H,m, CH), 3.05(2H,d, CH $_2$ ): $^{13}C$  NMR (75MHz, DMSO- $d_6$ )  $\delta$  66.5, 154.8, 149.4, 147.6, 141.3, 139, 126.4, 124.5, 122.7, 121.7, 120.7, 18.7, 14.5, 112.3, 111.6, 110.5, 104.2, 70.2, 66.5, 66.4, 55.4, 51.4, and 47.1)

**Step-3: Preparation of 1-(9H-carbazol-4-yloxy)-3[[2-(2-methoxy phenoxy) ethyl] amino]-2-propanol (Carvedilol)**

160 g of the oxalate salt is dissolved in 1500ml methylene chloride and to that 600 ml of water is charged. The pH is adjusted to pH 9.0-9.3 with aq ammonia. The reaction mass is stirred for one hr at room temp and the organic layer is separated. The aqueous layer is again extracted with 750ml of methylene chloride. The total methylene chloride layers are combined and dry over sodium sulphate followed by distillation of the methylene chloride. 700ml of ethyl acetate is charged and the system is refluxed for 15 minutes and then is slowly cooled to 10 $^{\circ}C$  and maintained at this temperature for two hrs. The material is filtered and washed with chilled ethyl acetate following by drying at 50 $^{\circ}C$ -60 $^{\circ}C$ . The resulting material was recrystallized in ethyl acetate.

Yield: 88 g (76% yield)  
M.P: 114 $^{\circ}C$  -116 $^{\circ}C$ .  
Purity: Above 99.5%

**Example-2:**

**Step-2: Preparation of 1-(9H-carbazol-4-yloxy)-3[[2-(2-methoxy phenoxy) ethyl] amino]-2-propanol oxalate (Carvedilol oxalate)**

146.4 g (0.875 moles, 2.1 mol equivalents) of 2-(2-methoxy phenoxy) ethylamine is dissolved in 500ml of monochlorobenzene and the temperature is raised 125 $^{\circ}C$  under stirring. 100 g (0.42 moles) of 4-(2,3-epoxy propoxy) carbazole is slowly added in lots over 1 hr at reflux temperature. Reflux is then carried on for two hrs. Distilled of the monochlorobenzene under vacuum followed by cooling of the reaction mass to 50-60 $^{\circ}C$ . 1000 ml isopropyl acetate is charged followed by the addition of 1000ml DMwater. pH of reaction mass is adjusted to 2.0-2.5 with 10% oxalic acid solution at 45 $^{\circ}C$  -50 $^{\circ}C$ . Stirred for one hr at 45 $^{\circ}C$  -50 $^{\circ}C$ , the



reaction mass is cooled to room temperature and maintained for two hrs. The material is filtered washed with isopropyl acetate and water mixture and then dried at 50°C -60°C.

Yield: 155 g (74.6% yield)

M.P: 184°C – 188 °C

- 5 (C,63.01: H,5.72:N,5.68:Calculated for C<sub>26</sub>H<sub>28</sub>N<sub>2</sub>O<sub>8</sub> C,62.90:,H,5.68,N,5.64:  
 IR Analysis: cm<sup>-1</sup> 3447,3056,1607,1456,1264, 1216, 1187, and 1024:1H NMR (300MHz, DMSO-d<sub>6</sub>) δ  
 11.25(1H,s, COOH), 8.2(1H,d, Ar-H), 7.44(1H,d, Ar-H), 7.30(2H,m, Ar-H), 7.10-7.15(2H,d, Ar-H), 6.80-  
 7.05(4H,m, Ar-H), 6.66(1H,d,Ar-H),4.25(2H,d,OCH<sub>2</sub>), 4.15(2H,t,OCH<sub>2</sub>), 3.70(3H,s, OCH<sub>3</sub>), 3.13 (2H,t, CH<sub>2</sub>) ,  
 3.11(1H,m,CH),3.05(2H,d,CH<sub>2</sub>):<sup>13</sup>C NMR (75MHz, DMSO-d<sub>6</sub>) δ 66.5,154.8,149.4,147.6, 141.3,  
 10 139,126.4,124.5,122.7,121.7,120.7, 18.7,14.5,112.3,111.6,110.5,104.2,70.2,66.5,66.4,55.4,51.4, and 47.1)

### Step-3: Preparation of 1-(9H-carbazol-4-yloxy)-3[[2-(2-methoxy phenoxy) ethyl] amino]- 2-propanol (Carvedilol)

This can be performed as described in Step-3 of Example-1

- 15 Yield: 88 g (63.2%)

M.P: 114°C -116°C.

### Example-3:

- Similarly was prepared the Carvedilol salicylate which is converted to Carvedilol in overall  
 20 yield of 59% from 2-(2-methoxy phenoxy) ethylamine

Analysis of carvedilol Salicylate:

- 25 ( C,68.4: H,6.03:N,5.44:Calculated for C<sub>31</sub>H<sub>32</sub>N<sub>2</sub>O<sub>7</sub> C,68.37:,H,5.92,N,5.14:IR Analysis: cm<sup>-1</sup> 3424,  
 2932,1457,1385,1256,1223,1179,1107,1027,754,and 721)

The present invention provides a novel, commercially feasible process to obtain Carvedilol Form-II of pharmaceutically acceptable quality using novel salts of Carvedilol without involving elaborative work-up. Further the present invention avoids the use of strong mineral acids thereby eliminating any possibility of decomposition of the product.

Claims

1. A process for the preparation of crystalline Carvedilol Form-II using novel salts of Carvedilol comprising steps:

- Reaction of 4-(2,3-epoxy propoxy) carbazole with 2-(2-methoxy phenoxy) ethyl amine in the molar ratio of 1:2.0 to 1:2.5 in organic solvents selected from monochlorobenzene, ethylene glycol, dimethyl ether (monoglyme) or their mixtures thereof.
- Adjustment of pH after completion of the reaction with organic acid(s) in presence of water, organic solvent(s) and isolation of novel Carvedilol salts.
- Treating the salts with base(s) in presence of water and methylene chloride followed by separation of the organic & aqueous layers.
- Drying of organic layer followed by removal of solvent and crystallization of the residue in ethyl acetate.

2. A process as claimed in claim 1, wherein the organic acid(s) is selected from oxalic acid and salicylic acid.

3. A process as claimed in claim 1, wherein the pH is adjusted to 2.0 to about 3.0 and preferably between 2.5 to about 2.8.

4. A process as claimed in claim 1, wherein the organic solvent(s) used during pH adjustment is selected from isopropyl acetate, chlorobenzene or mixtures thereof.

5. A process as claimed in claim 1, wherein the base(s) are selected from alkali, alkaline metal hydroxides, ammonia, organic bases such as triethyl amine, methylamine.

6. A process as claimed in claims 1 & 5 wherein the preferred base is aq. ammonia.

7. A process as claimed in claim 1, wherein the novel carvedilol salts are carvedilol oxalate and carvedilol salicylate.

8. A process for the preparation of carvedilol oxalate and carvedilol salicylate comprising

- 5
- Reaction of 4-(2,3-epoxy propoxy) carbazole with 2-(2-methoxy phenoxy) ethyl amine in the molar ratio of 1:2.0 to 1:2.5 in presence of suitable organic solvent(s).
  - Adjustment of pH after completion of the reaction with organic acid(s) in presence of water, organic solvent(s) and isolation of novel Carvedilol salts.

10 9. A process as claimed in claim 8, wherein the organic acid(s) is selected from oxalic acid and salicylic acid.

10. A process as claimed in claim 8, wherein the pH is adjusted to 2.0 to about 3.0 and preferably between 2.5 to about 2.8.

15

11. A process as claimed in claim 8, wherein the organic solvent(s) used during pH adjustment is selected from isopropyl acetate, chlorobenzene or mixtures thereof.

20

25

30

1 / 4




Figure - 1

2 / 4




Figure - 2

3 / 4




Figure - 3

4 / 4




Figure - 4

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IN 2004/000104

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C07D 209/88

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPOQUE: WPI, EPODOC; STN-Karlsruhe: CAS, CA-database

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO2002 000216 A1 (TEVA PHARMACEUTICAL INDUSTRIES LTD.) 3 January 2002 (03.01.2002) <i>examples 1, 2 and 4 - 6.</i>	1,8
A	WO1999 005105 A1 (BOEHRINGER MANNHEIM GMBH) 4 February 1999 (04.02.1999) <i>pages 5-7.</i>	1,8
A	EP 127099 A1 (BOEHRINGER MANNHEIM GMBH) 5 December 1984 (05.12.1984) <i>pages 17-18.</i>	1,8

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search  
15 August 2004 (15.08.2004)Date of mailing of the international search report  
7 September 2004 (07.09.2004)Name and mailing address of the ISA/ AT  
Austrian Patent Office  
Dresdner Straße 87, A-1200 ViennaAuthorized officer  
SLABY S.

Facsimile No. +43 / 1 / 534 24 / 535

Telephone No. +43 / 1 / 534 24 / 348



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IN 2004/000104

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 4920 A1 (BOEHRINGER MANNHEIM GMBH) 31 October 1979 (31.10.1979) page 9.</p> <p>----</p>	1,8

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/IN 2004/000104**

Patent document cited in search report			Publication date		Patent family member(s)	Publication date
EP	A	127099			CA A 1257279	1989-07-11
					IE L 841295L	1984-11-26
					DE D 3463768D	1987-06-25
					ES A 8502683	1985-04-16
					HU B 193011	1987-08-28
					HU A 34160	1985-02-28
EP	A	4920			NL I 930110I	1993-10-18
					AT A 276279	1984-01-15
					DE D 2960553D	1981-11-05
					SU A 810079	1981-02-28
					HU B 179433	1982-10-28
					IL A 57020	1982-07-30
WO	A	0216			none	
WO	A	9905105			HK A 1029339	2004-02-13
					US B 6730326	2004-05-04
					CA A 2296637	1999-02-04
					DE T 69812964T	2004-03-04
					ES T 2195366T	2003-12-01
					SI T 1000027T	2003-10-31